🚀 VC round data is live in beta, check it out!
SomnoMed Valuation Multiples
Discover revenue and EBITDA valuation multiples for SomnoMed and similar public comparables like Agfa-Gevaert, BioStem Technologies, Optiscan Imaging, Vivani Medical and more.
SomnoMed Overview
About SomnoMed
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
Founded
1987
HQ
Employees
4
Website
Sectors
Financials (LTM)
EV
$78M
SomnoMed Financials
SomnoMed reported last 12-month revenue of $84M and EBITDA of $8M.
In the same LTM period, SomnoMed generated $49M in gross profit, $8M in EBITDA, and $1M in net income.
Revenue (LTM)
SomnoMed P&L
In the most recent fiscal year, SomnoMed reported revenue of $78M and EBITDA of $6M.
SomnoMed expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $84M | XXX | $78M | XXX | XXX | XXX |
| Gross Profit | $49M | XXX | $47M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $8M | XXX | $6M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $1M | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | 1% | XXX | (1%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SomnoMed Stock Performance
SomnoMed has current market cap of $86M, and enterprise value of $78M.
Market Cap Evolution
SomnoMed's stock price is $0.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $78M | $86M | -7.2% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSomnoMed Valuation Multiples
SomnoMed trades at 0.9x EV/Revenue multiple, and 10.4x EV/EBITDA.
EV / Revenue (LTM)
SomnoMed Financial Valuation Multiples
As of April 11, 2026, SomnoMed has market cap of $86M and EV of $78M.
Equity research analysts estimate SomnoMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SomnoMed has a P/E ratio of 69.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $86M | XXX | $86M | XXX | XXX | XXX |
| EV (current) | $78M | XXX | $78M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | 10.4x | XXX | 13.1x | XXX | XXX | XXX |
| EV/EBIT | 26.5x | XXX | 51.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | 1.7x | XXX | XXX | XXX |
| P/E | 69.1x | XXX | (81.8x) | XXX | XXX | XXX |
| EV/FCF | (107.7x) | XXX | 27.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SomnoMed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SomnoMed Margins & Growth Rates
SomnoMed's revenue in the last 12 month grew by 11%.
SomnoMed's revenue per employee in the last FY averaged $19.6M, while opex per employee averaged $11.8M for the same period.
SomnoMed's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SomnoMed's rule of X is 35% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
SomnoMed Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 36% | XXX | 33% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $19.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $11.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 20% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SomnoMed Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Agfa-Gevaert | XXX | XXX | XXX | XXX | XXX | XXX |
| BioStem Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Optiscan Imaging | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivani Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Sera Prognostics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SomnoMed M&A Activity
SomnoMed acquired XXX companies to date.
Last acquisition by SomnoMed was on XXXXXXXX, XXXXX. SomnoMed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SomnoMed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSomnoMed Investment Activity
SomnoMed invested in XXX companies to date.
SomnoMed made its latest investment on XXXXXXXX, XXXXX. SomnoMed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SomnoMed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SomnoMed
| When was SomnoMed founded? | SomnoMed was founded in 1987. |
| Where is SomnoMed headquartered? | SomnoMed is headquartered in Australia. |
| How many employees does SomnoMed have? | As of today, SomnoMed has over 4 employees. |
| Is SomnoMed publicly listed? | Yes, SomnoMed is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of SomnoMed? | SomnoMed trades under SOM ticker. |
| When did SomnoMed go public? | SomnoMed went public in 2004. |
| Who are competitors of SomnoMed? | SomnoMed main competitors are Agfa-Gevaert, BioStem Technologies, Optiscan Imaging, Vivani Medical. |
| What is the current market cap of SomnoMed? | SomnoMed's current market cap is $86M. |
| What is the current revenue of SomnoMed? | SomnoMed's last 12 months revenue is $84M. |
| What is the current revenue growth of SomnoMed? | SomnoMed revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of SomnoMed? | Current revenue multiple of SomnoMed is 0.9x. |
| Is SomnoMed profitable? | Yes, SomnoMed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SomnoMed? | SomnoMed's last 12 months EBITDA is $8M. |
| What is SomnoMed's EBITDA margin? | SomnoMed's last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of SomnoMed? | Current EBITDA multiple of SomnoMed is 10.4x. |
| What is the current FCF of SomnoMed? | SomnoMed's last 12 months FCF is ($727K). |
| What is SomnoMed's FCF margin? | SomnoMed's last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of SomnoMed? | Current FCF multiple of SomnoMed is (107.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.